<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        9-5015-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CINFAVAL 80 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LABORATORIOS CINFA SA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            LABORATORIOS CINFA SA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cinfaval belongs to a class of medicines known as angiotensin II receptor antagonists, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Cinfaval works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.<br />Cinfaval can be used for three different conditions:<br />--<br />to treat high blood pressure in adult and in children and adolescents 6 to 18 years of age. High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.<br />--<br />to treat adult patients after a recent heart attack (myocardial infarction). &ldquo;Recent&rdquo; here means between 12 hours and 10 days.<br />--<br />to treat symptomatic heart failure in adult patients. Cinfaval is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used or it may be used in addition to ACE inhibitors when beta blockers (another medication to treat heart failure) cannot be used.<br />Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Cinfaval<br />--<br />If you are allergic (hypersensitive) to valsartan or to any of the other ingredients of Cinfaval.<br />--<br />If you suffer severe liver disease.<br />--<br />If you are more than 3 months pregnant (it is also preferable to avoid Cinfaval in early pregnancy &ndash; see pregnancy section).<br />--<br />If you have diabetes or severe kidney disease and you are treated with a blood pressure lowering medicine called aliskiren.<br />If any of these apply to you, do not take Cinfaval<br />Take special care with Cinfaval:<br />--<br />If you have a liver disease.<br />--<br />If you have severe kidney disease or if you are undergoing dialysis.<br />--<br />If you are suffering from a narrowing of the kidney artery.<br />--<br />If you have recently undergone kidney transplantation (received a new kidney).<br />--<br />If you are treated after a heart attack or for heart failure, your doctor may check your kidney function.<br />--<br />If you have severe heart disease other than heart failure or heart attack.<br />--<br />If you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin. It may be necessary to check the amount of potassium in your blood at regular intervals.<br />--<br />If you are below 18 years of age and you take Cinfaval in combination with other medicines that inhibit the renin angiotensin aldosterone system (medicines that lower blood pressure), your doctor may check your kidney function and the amount of potassium in your blood at regular intervals.<br />--<br />If you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of valsartan is not recommended.<br />--<br />If you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water pills (diuretics).<br />--<br />If you are pregnant, think you may be pregnant, or are planning to have a baby you must tell your doctor. Use of Cinfaval is not recommended at the start of pregnancy (first 3 months) and you must not take it in the last 6 months of pregnancy because it can cause serious damage to your baby, see section on Pregnancy and breast-feeding.<br />--<br />If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking Valsartan tablets, stop taking Valsartan immediately and never take it again. See also section 4, Possible side effects.<br />--<br />If you are taking any of the following medicines used to treat high blood pressure:<br />--<br />&ldquo;ACE inhibitors&rdquo; such as enalapril, lisinopril, etc.<br />--<br />Aliskiren.<br />If any of these apply to you, tell your doctor before you take Cinfaval<br />Taking other medicines<br />Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.<br />The effect of the treatment can be influenced if Cinfaval is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:<br />--<br />Other medicines that lower blood pressure, particularly water tablets (diuretics), angiotensin converting enzyme inhibitor (ACE inhibitor such as enalapril, lisinopril, etc.) or aliskiren.<br />--<br />Medicines that increase the amount of potassium in your blood. These include potassium-sparing medicines, potassium supplements or salt substitutes containing potassium and heparin.<br />--<br />Certain type of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs).<br />--<br />Lithium, a medicine used to treat some types of psychiatric illness.<br />--<br />Some antibiotics (rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (ritonavir). These drugs may increase the effect of Valsartan tablets.<br />In addition:<br />--<br />If you are being treated after a heart attack, a combination with ACE inhibitors (a medication to treat heart attack) is not recommended.<br />--<br />If you are being treated for heart failure, a triple combination with ACE inhibitors and beta blockers (medications to treat heart failure) is not recommended.<br />Taking Cinfaval with food and drink<br />Cinfaval can be administered with or without food.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />--<br />You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking Cinfaval before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Cinfaval. Cinfaval is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.<br />--<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Valsartan is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Cinfaval affects you. Like many other medicines used to treat high blood pressure, Cinfaval may in rare cases cause dizziness and affect the ability to concentrate.<br />Important information about some of the ingredients of Cinfaval<br />This medicine contains the sugars lactose and sorbitol. If your doctor has told you that you suffer intolerance to some sugars, ask him or her before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Cinfaval exactly as your doctor has told you in order to get the best results and reduce the risk of side effects.<br />People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.<br />Adult patients with high blood pressure<br />The usual dose is 80 mg once daily. In some cases your doctor may prescribe higher doses (e.g., 160 mg or 320 mg). He may also combine Cinfaval with an additional medicine (e.g. a diuretic).<br />Children and adolescents (6 to 18 years of age) with high blood pressure<br />In patients who weigh less than 35 kg the usual dose is 40 mg of valsartan once daily.<br />In patients who weigh 35 kg or more the usual starting dose is 80 mg of valsartan once daily.<br />In some cases your doctor may prescribe higher doses (the dose can be increased to 160 mg and to a maximum of 320 mg).<br />Adult patients after a recent heart attack:<br />After a heart attack, treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. You obtain the 20 mg dose by dividing the 40 mg tablet. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.<br />Cinfaval can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.<br />Adult patients with heart failure<br />Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate.<br />Cinfaval can be given together with other treatment for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>You can take Cinfaval with or without food. Swallow Cinfaval with a glass of water.<br />Take Cinfaval at about the same time each day.<br />If you take more Cinfaval that you should<br />If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.<br />If you forget to take Cinfaval<br />Do not take a double dose to make up a forgotten dose.<br />If you forget taking one dose, take it as soon as you remember. However, if it almost time for the next dose, wait for the next dose and take it at the usual time.<br />If you stop taking Cinfaval<br />Stopping your treatment with Valsartan may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.<br />If you have any further questions about the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Cinfaval can cause side effects, although not everybody gets them.<br />These side effects may occur with certain frequencies, which are defined as follows:<br />--<br />very common: affects more than 1 user in 10<br />--<br />common: affects 1 to 10 users in 100<br />--<br />uncommon: affects 1 to 10 users in 1,000<br />--<br />rare: affects 1 to 10 users in 10,000<br />--<br />very rare: affects less than 1 user in 10,000<br />--<br />not known: frequency cannot be estimated from the available data.<br />Some symptoms need immediate medical attention:<br />You might experience symptoms of angioedema (a specific allergic reaction), such as:<br />--<br />swollen face, lips, tongue or throat;<br />--<br />difficulty in breathing or swallowing;<br />--<br />hives, itching.<br />If you get any of these symptoms, stop taking Cinfaval and contact your doctor straight away (see also section 2 &ldquo;Take special care with Cinfaval&rdquo;).<br />Other side effects include:<br />Common:<br />--<br />dizziness<br />--<br />low blood pressure with or without symptoms such as dizziness and fainting when standing up<br />--<br />decreased kidney function (signs of renal impairment)<br />Uncommon:<br />--<br />angioedema (see section &ldquo;Some symptoms need immediate medical attention&rdquo;)<br />--<br />sudden loss of consciousness<br />--<br />spinning sensation (vertigo)<br />--<br />severely decreased kidney function (signs of acute renal failure)<br />--<br />muscle spasms, abnormal heart rhythm (signs of hyperkalaemia)<br />--<br />breathlessness, difficulty breathing when lying down, swelling of the feet or legs (signs of cardiac failure)<br />--<br />headache<br />--<br />cough<br />--<br />abdominal pain<br />--<br />nausea<br />--<br />diarrhoea<br />--<br />tiredness<br />--<br />weakness<br />Not known:<br />--<br />allergic reactions with rash, itching and hives; symptoms of fever, swollen joints and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms may occur (signs of serum sickness)<br />--<br />purplished-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis)<br />--<br />unusual bleeding or bruising (signs of thrombocytopenia)<br />--<br />muscle pain (myalgia)<br />--<br />fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia)<br />--<br />decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can lead to anaemia in severe cases)<br />--<br />increase of level of potassium in the blood (which can trigger muscle spasms and abnormal heart rhythm in severe cases)<br />--<br />elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases)<br />--<br />increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function)<br />--<br />low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases)<br />The frequency of some side effects may vary depending on your condition. For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in patients treated with high blood pressure than in patients treated for heart failure or after a recent heart attack.<br />Side effects in children and adolescents are similar to those seen in adults.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not store at a temperature above 30&ordm;C. Store in the original packaging.<br />Do not use Cinfaval after the expiry date which is stated on the container after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is valsartan. Each tablet contains 80 mg of valsartan.<br />The other ingredients are:<br />Tablet core: microcrystalline cellulose (E-460), colloidal anhydrous silica, sorbitol (E-420), magnesium carbonate (E-504), pregelatinised starch, povidone (E-1201), sodium stearyl fumarate, sodium lauryl sulphate and crospovidone.<br />Coating: Opadry OY-L-28900 (lactose monohydrate, hypromellose (E-464), titanium dioxide (E-171), macrogol).<br />Cinfaval 80 mg contains red iron oxide (E-172).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cinfaval 80 mg are scored, pink, cylindrical, coated tablets.
Cinfaval 80 mg is supplied in packages containing 28 tablets (in 7 tablets blister-packs).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><br />Marketing Authorisation Holder and Manufacturer<br />Laboratorios Cinfa, S.A.<br />Olaz-Chipi, 10 - Pol&iacute;gono Industrial Areta<br />31620 Huarte-Pamplona (Navarra) - Spain</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2013.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي سينفافال إلى فئة من العقاقير تعرف بـ &quot;مضادات مستقبلات الأنجيوتنسين الثاني&quot;، والتي تساعد في التحكم في ارتفاع ضغط الدم. الأنجيوتنسين الثاني؛ مادة يفرزها الجسم تسبب ضيقاً في الأوعية الدموية، الأمر الذي ينتج عنه ارتفاع في ضغط الدم. يعمل سينفافال من خلال تثبيط مفعول الأنجيوتنسين الثاني. ونتيجةً لذلك، ترتخي الأوعية الدموية وينخفض مستوى ضغط الدم..</p><p dir="RTL">يستخدم سينفافال لعلاج ثلاث حالات مرضية مختلفة:</p><p dir="RTL"><strong>- لعلاج ضغط الدم المرتفع للبالغين والأطفال والمراهقين من سن 6 إلى 18 عاماً</strong>. يؤدي ضغط الدم المرتفع إلى زيادة المجهود على القلب والشرايين. وفي حال عدم علاجه، قد يلحق الضرر بالأوعية الدموية في المخ والقلب والكُلى، مما يؤدي إلى الإصابة بسكتة دماغية أو قصور في القلب أو فشل كلوي. يزيد ضغط الدم المرتفع من خطر الإصابة بأزمات قلبية. يساعد خفض ضغط الدم إلى المستويات الطبيعية في تقليل خطر تطور الاضطرابات السابقة.</p><p dir="RTL">- <strong>لعلاج المرضى البالغين الذين تعرضوا مؤخراً للإصابة بأزمة قلبية </strong>(احتشاء عضلة القلب). الإصابة مؤخراً هنا تعني فترة ما بين 12 ساعة و10 أيام.</p><p dir="RTL">- <strong>لعلاج قصور القلب العرضي للمرضى البالغين</strong>. يستخدم سينفافال عند عدم إمكانية استخدام مجموعة من الأدوية تعرف بمثبطات الإنزيم المحول للأنجيوتنسين (عقار يستخدم لعلاج القصور في القلب) أو يمكن استخدامه مع مثبطات الإنزيم المحول للأنجيوتنسين عند عدم إمكانية استخدام حاصرات مستقبلات البيتا (عقار آخر لعلاج القصور في القلب).</p><p dir="RTL">تشمل أعراض القصور في القلب صعوبةً في التنفس وتورم القدمين والساقين نتيجة تراكم السوائل. تحدث الإصابة عندما لا تستطيع عضلة القلب ضخ الدم بالقدر الكافي لإمداد كل أجزاء الجسم بالدم الذي تحتاجه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; إذا كان لديك حساسية (حساسية مفرطة) لمادة الفالسارتان أو لأي مكون من المكونات الأخرى لدواء سينفافال.</p><p dir="RTL">- إذا كنت تعاني من مرض شديداَ فى الكبد.</p><p dir="RTL">- إذا تجاوزت فترة حملك ثلاثة أشهر (فيُفضل أيضاً عدم تناول سينفافال في مرحلة الحمل الأولى - انظر القسم الخاص بالحمل).</p><p dir="RTL">- إذا كنت مصاباً بداء السكري أو مرض شديد في الكُلى وتتم معالجتك بدواء لخفض ضغط الدم المرتفع يُعرف باسم الأليسكيرين.</p><p dir="RTL"><strong>إذا انطبق عليك أيٌّ من الحالات السابقة، فلا تتناول دواء سينفافال</strong></p><p dir="RTL"><strong>يجب توخي الحذر الشديد مع سينفافال</strong></p><p dir="RTL">- إذا كنت تعاني من مرض كبدي.</p><p dir="RTL">- إذا كنت تعاني من مرض شديد في الكُلى أو إذا كنت تخضع لعملية الغسيل الكلوي.</p><p dir="RTL">- إذا كنت تعاني من ضيق في الشريان الكلوي.</p><p dir="RTL">- إذا خضعت مؤخراً لعملية زرع الكُلى (زراعة كلية جديدة).</p><p dir="RTL">- إذا كنت تتلقى العلاج بعد الإصابة بأزمة قلبية أو قصور في القلب، فقد يقوم طبيبك بفحص وظائف الكلى.</p><p dir="RTL">- إذا كنت تعاني من مرض شديد في القلب غير القصور في القلب أو الأزمة القلبية.</p><p dir="RTL">- إذا كنت تتناول أي أدوية تعمل على رفع مستوى البوتاسيوم في الدم. وتشمل مكملات البوتاسيوم أو بدائل الملح التى تحتوى على البوتاسيوم أو الأدوية الحافظة للبوتاسيوم والهيبارين. قد يكون من الضروري فحص مستوى البوتاسيوم في الدم على فترات زمنية منتظمة.</p><p dir="RTL">- إذا كنت أقل من 18 عاماً وتتناول سينفافال مع أدوية أخرى تعمل على تثبيط نظام الرينين-أنجيوتنسين-ألدوستيرون (الأدوية التي تعمل على خفض ضغط الدم)، يجب أن يقوم الطبيب بفحص وظائف الكُلى ومستوى البوتاسيوم في الدم على فترات زمنية منتظمة.</p><p dir="RTL">- &bull; إذا كنت تعاني من مرض الألدوستيرونية. وهو مرض تقوم فيه الغدة الكظرية بإفراز كميات كبيرة من هرمون الألدوستيرون. إذا كانت هذه الحالة تنطبق عليك، فلا يُنصح بتناول مادة الفالسارتان.</p><p dir="RTL">- عند فقد الكثير من السوائل (الجفاف) الناتج عن الإسهال أو القيء أو تناول جرعات كبيرة من أقراص المياه (مدرات البول ).</p><p dir="RTL">- في حالة الحمل أو التخطيط للحمل أو إذا كنت تعتقدين بوجود الحمل، يُرجى إخبار الطبيب. لا ينصح باستخدام سينفافال في بداية الحمل (الأشهر الثلاثة الأولى) كما يجب عدم تناوله خلال الأشهر الستة الأخيرة من الحمل إذ قد يؤدي ذلك إلى إلحاق ضرر بالغ بطفلك، انظر قسم &quot;الحمل والرضاعة&quot;.</p><p dir="RTL">- إذا كنت قد تعرضت مسبقاً لحدوث تورم في اللسان والوجه نتيجةً لأحد تفاعلات الحساسية والتي تُعرف باسم الوذمة الوعائية عند تناول دواء آخر (بما في ذلك مثبطات الإنزيم المحول للأنجيوتنسين)، فلتخبر طبيبك بذلك. في حال ظهور هذه الأعراض عند تناول أقراص فالسارتان، توقف عن تناول هذا الدواء على الفور ولا تتناول مجدداً. انظر أيضاً القسم 4، &quot;الآثار الجانبية المحتملة&quot;.</p><p dir="RTL">- إذا كنت تتناول الأدوية التالية لعلاج ضغط الدم المرتفع:</p><p dir="RTL">- &quot;مثبطات الإنزيم المحول للأنجيوتنسين&quot; مثل إنالابريل، ليزينوبريل وغير ذلك.</p><p dir="RTL">- أليسكيرين.</p><p dir="RTL"><strong>إذا انطبق عليك أي من الحالات السابقة، فاستشر الطبيب قبل تناول سينفافال</strong></p><p dir="RTL"><strong>التفاعلات مع الأدوية الأخرى</strong></p><p dir="RTL">يُرجى إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أي أدوية أخرى، بما في ذلك الأدوية التي تصرف دون وصفة طبية.</p><p dir="RTL">يمكن أن تتأثر فاعلية الدواء في حال تناول سينفافال مع أدوية أخرى محددة. قد يتطلب الأمر تغيير الجرعة أو اتخاذ احتياطات أخرى أو في بعض الحالات التوقف عن تناول أحد الأدوية. ينبطق ذلك على الأدوية التي تؤخذ بوصفة طبية أو دون وصفة طبية خاصةً:</p><p dir="RTL">- الأدوية الأخرى التي تعمل على خفض ضغط الدم خاصةً أقراص المياه (مدرات البول) أو مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، ليزينوبريل وغير ذلك) أو الأليسكيرين.</p><p dir="RTL">- الأدوية التي تعمل على رفع مستوى البوتاسيوم في الدم. ويشمل ذلك الأدوية الحافظة للبوتاسيوم أو مكملات البوتاسيوم أو بدائل الملح التى تحتوى على البوتاسيوم والهيبارين.</p><p dir="RTL">- نوعاً معيناً من المسكنات يعرف بمضادات الإلتهاب غير الستيروئيدية (NSAIDs).</p><p dir="RTL">- الليثيوم، وهو دواء يُستخدم لعلاج بعض أنواع الأمراض النفسية.</p><p dir="RTL">- بعض المضادات الحيوية (مجموعة ريفامايسين)، مثل العقار المستخدم للوقاية من رفض الجسم للأعضاء المزروعة (السيكلوسبورين) أو العقار المضاد للفيروسات القهقرية المستخدم لعلاج عدوى فيروس نقص المناعة (الأيدز)/متلازمة نقص المناعة المكتسبة (ريتونافير). قد تؤدي هذه العقاقير إلى زيادة تأثير أقراص فالسارتان.</p><p dir="RTL"><strong>إضافة إلى ذلك:</strong></p><p dir="RTL">- إذا كنت تخضع للعلاج بعد <strong>الإصابة بأزمة قلبية</strong>، فلا يُنصح باستخدام هذا الدواء مع مثبطات الإنزيم المحول للأنجيوتنسين (دواء يؤخذ لعلاج الأزمة القلبية).</p><p dir="RTL">- إذا كنت تخضع للعلاج نتيجة الإصابة <strong>بقصور في القلب</strong>، فلا يُنصح باستخدام هذا الدواء مع مثبطات الإنزيم المحول للأنجيوتنسين <strong>وحاصرات مستقبلات البيتا</strong> (دواء يؤخذ لعلاج القصور في القلب).</p><p dir="RTL"><strong>تناول سينفافال مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول سينفافال مع الطعام أو بدونه.</p><p dir="RTL"><strong>الحمل والإرضاع</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p><p dir="RTL"><strong>- يجب أن تخبري طبيبكِ إذا كنت تعتقدين بوجود حمل (أو تخططين لذلك).</strong> سينصحكِ الطبيب عادةً بالتوقف عن تناول سينفافال قبل أن تصبحي حاملاً أو بمجرد معرفتك أنك حامل وسينصحكِ بتناول دواء آخر بدلاً من سينفافال. لا يُنصح باستعمال سينفافال خلال مرحلة الحمل الأولى ولا يجب تناوله إذا تجاوزت فترة حملك ثلاثة أشهر، فمن المحتمل أن يُلحِق ضرراً بالغاً بطفلك في حال استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL">- <strong>أخبري طبيبك إذا كنتِ تُرضعين أو على وشك الإرضاع.</strong> لا يُنصح باستعمال سينفافال من قبل الأمهات أثناء فترة الإرضاع، وقد يختار طبيبك علاجاً آخر إذا كنت ترغبين في الإرضاع، وخاصة إذا كان طفلك حديث الولادة أو مولوداً قبل أوانه.</p><p dir="RTL"><strong>القيادة وتشغيل الآلات</strong></p><p dir="RTL">قبل قيادة المركبات، أو استخدام الأدوات أو تشغيل الآلات أو القيام بأي أنشطة أخرى تتطلب التركيز، تأكد من مدى تأثير سينفافال عليك. كما هو حال العديد من الأدوية الأخرى المستخدمة في علاج ضغط الدم المرتفع، قد يسبب سينفافال في حالات نادرة في الشعور بالدوار ويؤثر في قدرتك على التركيز.</p><p dir="RTL"><strong>معلومات مهمة حول بعض مكونات سينفافال</strong></p><p dir="RTL">يحتوي هذا الدواء على سكر اللاكتوز والسوربيتول. إذا كان طبيبك قد أوضح لك أنك تعاني حساسية لبعض أنواع السكر، فعليك إستشارته قبل تناول هذا المنتج الدوائي.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دواء <strong>سينفافال</strong> دائماً حسب وصف الطبيب للحصول على أفضل النتائج وتقليل خطر ظهور الآثار الجانبية.</p><p dir="RTL">إن مرضى ضغط الدم المرتفع لا يلاحظون في الغالب أعراض هذه المشكلة. الكثير منهم يشعرون بصحة جيدة. لذلك من الأهمية بمكان الحرص على زيارة طبيبك في المواعيد المحددة حتى وإن كنت تشعر بصحة جيدة.</p><p dir="RTL"><strong>المرضى البالغون المصابون بضغط دم مرتفع</strong></p><p dir="RTL">تبلغ الجرعة العادية الموصى بها 80 ملجم مرة واحدة يومياً. قد يصف الطبيب في بعض الحالات تناول جرعات أكبر (على سبيل المثال، 160 ملجم أو 320 ملجم). قد يصف الطبيب تناول سينفافال مع علاجات أخرى (مثل مدرات البول).</p><p dir="RTL"><strong>الأطفال والمراهقون (تتراوح أعمارهم بين 6 و18 عاماً) المصابون بضغط الدم المرتفع</strong></p><p dir="RTL">في حالة المرضى الذين يقل وزنهم عن 35 كجم، تبلغ الجرعة العادية من فالسارتان 40 ملجم مرة واحدة يومياً.</p><p dir="RTL">في حالة المرضى الذين يصل وزنهم إلى 35 كجم أو أكثر، تبلغ الجرعة الأولى العادية من فالسارتان 80 ملجم مرة واحدة يومياً.</p><p dir="RTL">قد يصف الطبيب في بعض الحالات تناول جرعات أكبر (قد تصل الجرعة إلى 160 ملجم وبحد أقصى 320 ملجم).</p><p dir="RTL"><strong>المرضى البالغون الذين تعرضوا مؤخراً للإصابة بأزمة قلبية:</strong></p><p dir="RTL">عند الإصابة بأزمة قلبية، يبدأ العلاج بشكل عام بعد 12 ساعة من الإصابة بتناول جرعة منخفضة تصل إلى 20 ملجم تؤخذ مرتين يومياً. ويمكنك الحصول على جرعة مقدارها 20 ملجم بتقسيم قرص 40 ملجم إلى نصفين. يقوم الطبيب بعد ذلك بزيادة الجرعة تدريجياً على مدار عدة أسابيع بحد أقصى 160 ملجم تؤخذ مرتين يومياً. تعتمد الجرعة النهائية على قدرة تحمل كل مريض.</p><p dir="RTL">يمكن تناول سينفافال مع الأدوية الأخرى التي تعالج الأزمة القلبية وسيحدد الطبيب العلاج المناسب لك.</p><p dir="RTL"><strong>المرضى البالغون المصابون بقصور في القلب</strong></p><p dir="RTL">يبدأ العلاج بشكل عام بتناول جرعة تبلغ 40 ملجم من الدواء تؤخذ مرتين يومياً. يقوم الطبيب بعد ذلك بزيادة الجرعة تدريجياً على مدار عدة أسابيع بحد أقصى 160 ملجم تؤخذ مرتين يومياً. تعتمد الجرعة النهائية على قدرة تحمل كل مريض.</p><p dir="RTL">يمكن تناول سينفافال مع الأدوية الأخرى التي تعالج القصور في القلب وسيحدد الطبيب العلاج المناسب لك.</p><p dir="RTL">يمكنك تناول سينفافال مع الطعام أو بدونه. &bull; ابتلع أقراص سينفافال مع كوب من الماء.</p><p dir="RTL">تناول أقراص سينفافال في نفس الوقت كل يوم.</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من سينفافال</strong></p><p dir="RTL">إذا كنت تشعر بدوار شديد و/أو إغماء، فلتستلقِ وتتصل بطبيبك على الفور. إذا تناولت عدداً كبيراً جداً من الأقراص عن طريق الخطأ، فاتصل بالطبيب أو الصيدلي أو المستشفى.</p><p dir="RTL"><strong>إذا نسيت تناول سينفافال</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">إذا نسيت تناول جرعة واحدة، فتناولها بمجرد تذكرك. إذا كان ذلك وقت الجرعة التالية تقريباً، فأنتظر ميعاد الجرعة التالية وتناولها في وقتها المحدد.</p><p dir="RTL"><strong>إذا توقفت عن تناول سينفافال</strong></p><p dir="RTL">قد يتسبب التوقف عن العلاج بدواء سينفافال إلى زيادة حدة المرض. لا تتوقف عن تناول الدواء حتى يخبرك الطبيب بذلك.</p><p>إذا كان لديك أي أسئلة أخرى عن طريقة استخدام هذا المنتج، فاسأل الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثاراً جانبية، ولكنها لا تظهر بالضرورة على كل من يتناوله.</p><p dir="RTL">تتفاوت درجات حدوث الآثار الجانبية، وتُعرف كالتالي:</p><p dir="RTL">- آثار جانبية شائعة جداً: قد تؤثر في مستخدم واحد من بين كل 10</p><p dir="RTL">- شائعة: قد تؤثر في عدد يتراوح بين 1 و10 مستخدمين من بين كل 100</p><p dir="RTL">- غير شائعة: قد تؤثر في عدد يتراوح بين 1 و10 مستخدمين من بين كل 1,000</p><p dir="RTL">- نادرة: قد تؤثر في عدد يتراوح بين 1 و10 مستخدمين من بين كل 10,000</p><p dir="RTL">- شديدة الندرة: قد تؤثر في مستخدم واحد من بين كل 10,000</p><p dir="RTL">- غير معروفة: لا يمكن تقييم عدد مرات حدوثها من البيانات المتاحة.</p><p dir="RTL"><strong>قد تحتاج بعض الأعراض إلى عناية الطبيب الفورية:</strong></p><p dir="RTL">قد يظهر عليك أعراض مرض الوذمة الوعائية (أحد تفاعلات الحساسية) مثل:</p><p dir="RTL">-&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق</p><p dir="RTL">-&nbsp; صعوبة في التنفس أو البلع</p><p dir="RTL">- شرى، حكة.</p><p dir="RTL"><strong>في حال ظهور أيٍّ من الأعراض السابقة، فتوقف عن تناول سينفافال واتصل بالطبيب على الفور (انظر القسم 2 &quot;توخي الحذر الشديد عند استخدام سينفافال&quot;).</strong></p><p dir="RTL">تشمل الآثار الجانبية الأخرى:</p><p dir="RTL"><strong>شائعة:</strong></p><p dir="RTL">- الدوار</p><p dir="RTL">- انخفاض ضغط الدم مع ظهور أعراض مثل الدوار والإغماء عند الوقوف أو عدم ظهورها</p><p dir="RTL">-إنخفاض أداء وظائف الكلى (علامات قصور حاد بالكُلى)</p><p dir="RTL"><strong>غير شائعة:</strong></p><p dir="RTL">-&nbsp; الوذمة الوعائية (انظر القسم بعنوان &quot;بعض الأعراض التي تحتاج إلى عناية الطبيب الفورية&quot;)</p><p dir="RTL">- فقدان الوعي المفاجئ</p><p dir="RTL">- الشعور بدوار (الدوخة)</p><p dir="RTL">- ضعفاً حاداً في أداء وظائف الكلى (علامات قصور حاد بالكُلى)</p><p dir="RTL">- تشنجات عضلية، عدم انتظام معدل ضربات القلب (علامات زيادة بوتاسيوم الدم)</p><p dir="RTL">- ضيق التنفس أو صعوبة في النتفس عند الاستلقاء أو تورم القدمين أو الساقين (علامات القصور في عضلة القلب)</p><p dir="RTL">- صداع<strong> </strong></p><p dir="RTL">- سعال</p><p dir="RTL">- ألم في منطقة البطن</p><p dir="RTL">- غثيان</p><p dir="RTL">- إسهال</p><p dir="RTL">- شعور بالتعب</p><p dir="RTL">- شعور بالضعف</p><p dir="RTL"><strong>غير معروفة:</strong></p><p dir="RTL">- قد يحدث تفاعلات حساسية مصحوبة ببعض الأعراض مثل طفح جلدي، حكة، شرى، حمى، آلام المفاصل وتورمها، ألم في العضلات، تورم الغدد الليمفاوية و/أو أعراض تُشبه الإنفلونزا (علامات داء المصل)</p><p dir="RTL">- بقع حمراء مائلة إلى اللون الأرجواني، حمى، حكة (علامات التهاب الأوعية الدموية)</p><p dir="RTL">- نزيف غير طبيعي أو ظهور كدمات (علامات قلة الصفائح الدموية)</p><p dir="RTL">- ألم في العضلات</p><p dir="RTL">- حمى أو التهاب الحلق أو تقرح الفم نتيجة للعدوى (أعراض انخفاض مستوى خلايا الدم البيضاء والمعروف أيضاً بأنخفاض العادلات)</p><p dir="RTL">-&nbsp; انخفاض مستوى الهيموجلوبين والنسبة المئوية لخلايا الدم الحمراء في الدم (مما يسبب، في الحالات الشديدة، مرض فقر الدم).</p><p dir="RTL">- زيادة مستوى البوتاسيوم في الدم (مما قد ينتج عنه تشنجات عضلية وعدم انتظام معدل ضربات القلب في الحالات الشديدة)</p><p dir="RTL">- ارتفاعاً في قيم وظائف الكبد (مما يشير إلى تلف خلايا الكبد) ويشمل ذلك زيادة مستوى البيليروبين في الدم (والذي قد يتسبب، في الحالات الشديدة، في اصفرار البشرة والعينين)</p><p dir="RTL">-&nbsp; زيادة نسبة تركيز النيتروجين في اليوريا بالدم وارتفاع مستوى كرياتينين المصل (مما يشير إلى حدوث قصور في وظائف الكُلى)</p><p dir="RTL">- انخفاض مستوى الصوديوم في الدم (مما قد ينتج عنه شعور بالإجهاد والارتباك وتشنج في العضلات و / أو الاختلاجات في الحالات الشديدة)</p><p dir="RTL">قد يتغير معدل تكرار ظهور الأعراض الجانبية وفقاً لحالتك. فعلى سبيل المثال، بعض الآثار الجانبية مثل الدوار وانخفاض وظائف الكُلى ظهرت في المرضى الذين يعالجون من ارتفاع ضغط الدم بمعدل أقل من ظهورها في المرضى الذين يعالجون من القصور في القلب أو الذين أصيبوا مؤخراً بأزمة قلبية.</p><p dir="RTL">تتشابه الآثار الجانبية لدى الأطفال والمراهقين مع تلك الآثار التي تظهر لدى البالغين.</p><p dir="RTL"><strong>إذا تطور أيٌّ من هذه الآثار الجانبية لدرجة خطيرة، أو إذا لاحظت حدوث أي آثار جانبية غير مدرجة بهذه النشرة، فأخبر الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن مرأى و متناول الأطفال.</p><p dir="RTL">يُحفظ الدواء في درجة حرارة لا تزيد عن 30 ْم، ويُحفظ في عبوته الأصلية.</p><p dir="RTL">لا يستعمل هذا الدواء بعد انتهاء تاريخ الصلاحية الموضح على العلبة بعد كلمة EXP. يشير تاريخ الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">لا ينبغي التخلص من أي أدوية عن طريق مياه الصرف أو النفايات المنزلية. إسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد تستعملها. تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- يتوفر دواء سينفافال في شكل أقراص مغلفة.</p><p dir="RTL"><strong>يحتوي سينفافال على:</strong></p><p dir="RTL">المادة الفعالة وهي فالسارتان. يحتوي كل قرص على 80 ملجم من الفالسارتان.</p><p dir="RTL">أما المكونات الأخرى فهي:</p><p dir="RTL">&nbsp;محتوى القرص من الداخل: سليلوز دقيق البللورات (E-460)، سيليكا غروانية لا مائية، سوربيتول (E-420)، كربونات مغنيسيوم (E-504)، نشا محول مسبقاً إلى جيلاتين، بوفيدون (E-1201)، فومارات ستيريل الصوديوم، سلفات لوريل الصوديوم، كروسبوفيدون.</p><p dir="RTL">يحتوى الغلاف على: أوبادري OY-L-28900 (مونوهيدرات اللاكتوز، هايبروميلوز (E464)، ثاني أكسيد التيتانيوم (E171)، ماكروغول).</p><p dir="RTL">يحتوي قرص سينفافال 80 ملجم على أكسيد الحديد الأحمر (E-172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتوفر أقراص سينفافال 80 ملجم في شكل أقراص مغلفة مقسومة من المنتصف وأسطوانية وذات لون وردي.</p><p dir="RTL">تتوفر أقراص سينفافال 80 ملجم في عبوة تحتوي على 28 قرصاً (7 أقراص فى كل شريط).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مختبرات سينفا، ش.م.</p><p dir="RTL">شارع أولاز شيبي، 10 منطقة بوليغنو الصناعية</p><p dir="RTL">31620 أوارتي-بامبلونا (نافارا) - إسبانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أجريت آخر مراجعة لهذه النشرة في مايو 2013 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cinfaval 80 mg film-coated tablets 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 80 mg of valsartan.
valsartan cinfa 80 mg film-coated tablets
contains sorbitol........................9.25 mg
contains lactose.........................1.08 mg
See section 6.1 for the complete list of excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                scored, pink, cylindrical, coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension<br />Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18 years of age.<br />Recent myocardial infarction<br />Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours &ndash; 10 days) myocardial infarction (see sections 4.4 and 5.1).<br />Heart Failure<br />Treatment of symptomatic heart failure when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta blockers cannot be used (see sections 4.4 and 5.1).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Hypertension<br />The recommended starting dose of Cinfaval is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg.<br />Cinfaval may also be administered with other antihypertensive agents (see section 4.3, 4.4, 4.5 and 5.1). The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.<br />Recent myocardial infarction<br />In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, valsartan should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet.<br />The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&rsquo;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction.<br />Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).<br />Evaluation of post-myocardial infarction patients should always include assessment of renal function.<br />Heart failure<br />The recommended starting dose of Cinfaval is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.<br />Valsartan may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, a beta blocker and valsartan is not recommended (see sections 4.4 and 5.1).<br />Evaluation of patients with heart failure should always include assessment of renal function.<br />Additional information on special populations<br />Elderly<br />No dose adjustment is required in elderly patients.<br />Renal impairment<br />No dose adjustment is required for adult patients with a creatinine clearance &gt;10 ml/min (see sections 4.4 and 5.2). Concomitant use of Cinfaval with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73m2) (see section 4.3).<br />DiabetesMellitus<br />Concomitant use of Cinfaval with aliskiren is contraindicated in patients with diabetes mellitus (see section 4.3).<br />Hepaticimpairment<br />2<br />Cinfaval is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of valsartan should not exceed 80 mg.<br />Paediatricpopulation<br />Paediatric hypertension<br />Children and adolescents 6 to 18 years of age<br />The initial dose is 40 mg once daily for children weighing below 35 kg and 80 mg once daily for those weighing 35 kg or more. The dose should be adjusted based on blood pressure response. For maximum doses studied in clinical trials please refer to the table below.<br />Doses higher than those listed have not been studied and are therefore not recommended. Weight Maximum dose studied in clinical trials<br />&ge;18 kg to &lt;35 kg 80 mg<br />&ge;35 kg to &lt;80 kg 160 mg<br />&ge;80 kg to &le;160 kg 320 mg<br />Children less than 6 years of age<br />Available data are described in sections 4.8, 5.1 and 5.2. However safety and efficacy of Cinfaval in children aged 1 to 6 years have not been established.<br />Use in paediatric patients aged 6 to 18 years with renal impairment<br />Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore Cinfaval is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).<br />Use in paediatric patients aged 6 to 18 years with hepatic impairment<br />As in adults, Cinfaval is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with valsartan in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.<br />Paediatric heart failure and recent myocardial infarction<br />Cinfaval is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18 years due to the lack of data on safety and efficacy.<br />Method of administration<br />Cinfaval may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Severe hepatic impairment, biliary cirrhosis and cholestasis.
- Second an third trimester of pregnancy (see sections 4.4 and 4.6).
- The concomitant use of Cinfaval with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m2) (see sections 4.5 and 5.1).
3
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hyperkalaemia<br />Concomitant use with potassiumsupplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended.<br />Monitoring of potassium should be undertaken as appropriate.<br />Sodium- and/or volume-depleted patients<br />In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Cinfaval.<br />Sodium and/or volume depletion should be corrected before starting treatment with Cinfaval, for example by reducing the diuretic dose.<br />Renal artery stenosis<br />In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of Cinfaval has not been established.<br />Short-term administration of Cinfaval to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with valsartan.<br />Kidney transplantation<br />There is currently no experience on the safe use of Cinfaval in patients who have recently undergone kidney transplantation.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism should not be treated with Cinfaval as their renin-angiotensin system is not activated.<br />Aortic andmitral valve stenosis, obstructive hypertrophic cardiomyopathy<br />As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).<br />Impaired renal function<br />There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients. No dose adjustment is required for adult patients with a creatinine clearance &gt;10 ml/min (see sections 4.2 and 5.2). The concomitant use of AIIRAs, including Cinfaval or of ACE inhibitors with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see sections 4.3 and 4.5).<br />Hepaticimpairment<br />In patients with mild to moderate hepatic impairment without cholestasis, Cinfaval should be used with caution (see sections 4.2 and 5.2).<br />Pregnancy (Fetal toxicity)<br />4<br />Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />When pregnancy is detected, discontinue Valsartan as soon as possible.<br />Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.<br />Recent-myocardial infarction<br />The combination of captopril and valsartan has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of valsartan with an ACE inhibitor is not recommended.<br />Caution should be observed when initiating therapy in post-myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2).<br />Use of Cinfaval in post-myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).<br />Heart Failure<br />In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and Cinfaval has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended.<br />Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2).<br />Use of Cinfaval in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).<br />Other conditions with stimulation of the renin-angiotensin system<br />In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As Cinfaval is an angiotensin II antagonist, it cannot be excluded that the use of Cinfaval may be associated with impairment of the renal function.<br />History of angioedema<br />Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with Cinfaval; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Cinfaval should be immediately discontinued in patients who develop angioedema, and Cinfaval should not be re-administered (see section 4.8).<br />Dual Blockade of the Renin-Angiotensin-Aldosterone System(RAAS)<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). Therefore, this combination should not be used, especially in patients with kidney problems.<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood<br />5<br />pressure. ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.<br />Paediatricpopulation<br />Impaired renal function<br />Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with valsartan. This applies particularly when valsartan is given in the presence of other conditions (fever, dehydration) likely to impair renal function. The concomitant use of AIIRAs, including Cinfaval or of ACE inhibitors with aliskiren is contraindicated in patients with renal impairment (GFR &lt; 60 mL/min/1.73 m2) (see sections 4.3 and 4.5).<br />Impaired hepatic function<br />As in adults, Cinfaval is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with Cinfaval in paediatric patients with mild to moderate hepatic impairment. The dose of valsartan should not exceed 80 mg in these patients.<br />Warning about the excipients:<br />This medicine contains sorbitol. Patients with hereditary intolerance to fructose should not take this medicine.<br />This medicine contains lactose. Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dual blockage of the Renin-Angiotensin-System (RAS) with AIIRAs, ACE inhibitors, or aliskiren:<br />Concomitant use of Angiotensin II Receptor Antagonists (ARBs), including Cinfaval, or of Angiotensin Converting Enzyme (ACE) inhibitors with aliskiren in patients with diabetes mellitus or renal impairment (GFR &lt; 60 ml/min/1.73 m2) is contraindicated (see sections 4.3).<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). Therefore, this combination should not be used, especially in patients with kidney problems.<br />Concomitant use not recommended Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors. Due to the lack of experience with concomitant use of valsartan and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.<br />Potassium-sparing diuretics, potassiumsupplements, salt substitutes containing potassiumand other substances that may increase potassium levels<br />If a medicinal product that affects potassium levels is considered necessary in combination with valsartan, monitoring of potassium plasma levels is advised.<br />6<br />Caution required with concomitant use<br />Non-steroidal anti-inflammatory medicines (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs<br />When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.<br />Transporters<br />In vitro data indicates that valsartan is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporterMRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to valsartan. Exercise appropriate care when initiating or ending concomitant treatment with such drugs.<br />Others<br />In drug interaction studies with Cinfaval, no interactions of clinical significance have been found with valsartan or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.<br />Paediatricpopulation<br />In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of valsartan and other substances that inhibit the renin angiotensin aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy (Pregnancy category D)<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded.Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti- hypertensive treatments which have an established safety profile for use in pregnancy.When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.<br />AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also<br />The use of Angiotensin II Receptor Antagonists (AIIRAs) is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contra-indicated during the second and third trimester of pregnancy (see sections 4.3 and 4.4).<br /><br />Breastfeeding<br />Because no information is available regarding the use of valsartan during breastfeeding, Cinfaval is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.<br />Fertility<br />Valsartan had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed.When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies in adult patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the pharmacology of valsartan. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.<br />The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.<br />Adverse reactions are ranked by frequency, the most frequent first, using the following convention: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000) very rare (&lt; 1/10,000), including isolated reports.Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.<br />For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.<br />Hypertension<br />Blood and lymphatic system disorders<br />Unknown frequency Reduction of haemoglobin, reduction of<br />haematocrit, neutropaenia, thrombocytopaenia<br />Immune system disorders<br />Unknown frequency Hypersensitivity including serum sickness<br />Metabolism and nutrition disorders<br />Unknown frequency Increase in serum potassium<br />Ear and labyrinth disorders<br />Uncommon Dizziness<br />Vascular disorders<br />Unknown frequency Vasculitis<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon Cough<br />Gastrointestinal disorders<br />Uncommon Abdominal pain<br />Hepatobiliary disorders<br />Unknown frequency Rise in hepatic function values, including increase<br />in serum bilirubin<br />Skin and subcutaneous tissue disorders<br />Unknown frequency Angioedema, rash, itching.<br />Musculoskeletal and connective tissue disorders<br />Unknown frequency Myalgia<br />Renal and urinary disorders<br />Unknown frequency Renal failure and impairment, increase in serum<br />creatinine<br />General disorders and administration site conditions<br />Uncommon Fatigue<br />The safety profile observed in controlled clinical studies in patients after a myocardial infarction and/or heart<br />failure is different from the general safety profile observed in hypertensive patients. This may be related to<br />the patients&#39; underlying disease. The UEs that occurred in patients after a myocardial infarction and/or heart<br />failure are listed below:<br /> After a myocardial infarction and/or heart failure<br />Blood and lymphatic system disorders<br />Unknown frequency Thrombocytopenia<br />Immune system disorders<br />Unknown frequency Hypersensitivity including serum sickness<br />Metabolism and nutrition disorders<br />Uncommon Hyperpotassaemia<br />Unknown frequency Increase in serum potassium<br />Nervous system disorders<br />Common Dizziness, postural dizziness<br />Uncommon Syncope, Headache<br />Ear and labyrinth disorders<br />Uncommon Vertigo<br />Cardiac disorders<br />Uncommon Heart failure<br />Vascular disorders<br />Common Hypotension, orthostatic hypotension<br />Unknown frequency Vasculitis<br />Respiratory, thoracic and mediastinal disorders<br />Uncommon Cough<br />Gastrointestinal disorders<br />Uncommon Nausea, diarrhoea<br />Hepatobiliary disorders<br />Unknown frequency Increased liver function values<br />Skin and subcutaneous tissue disorders<br />Uncommon Angioedema<br />Unknown frequency Rash, itching<br />Musculoskeletal and connective tissue disorders<br />Unknown frequency Myalgia<br />Renal and urinary disorders<br />Common Renal failure and impairment<br />Uncommon Acute renal failure, increase in serum creatinine<br />Unknown frequency Increase in blood urea nitrogen<br />General disorders and administration site conditions<br />Uncommon Asthenia, fatigue</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />Overdose with Cinfaval may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.<br />Treatment<br />The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.<br />If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.<br />Valsartan is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03<br />Valsartan is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with valsartan may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor.<br />Valsartan does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Valsartan is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation. Valsartan does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where valsartan was compared with an ACE inhibitor, the incidence of dry cough was significantly (P&lt;0.05) less in patients treated with valsartan than in those treated with an ACE inhibitor (2.6% versus 7.9 % respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5 % of trial subjects receiving valsartan and 19.0 % of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (P &lt; 0.05).<br />Hypertension<br />Administration of Cinfaval to patients with hypertension results in reduction of blood pressure without affecting pulse rate.<br />In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a<br />11<br />significant additional reduction in blood pressure is achieved.<br />Abrupt withdrawal of Cinfaval has not been associated with rebound hypertension or other adverse clinical events.<br />In hypertensive patients with type 2 diabetes and microalbuminuria, valsartan has been shown to reduce the urinary excretion of albumin. TheMARVAL (Micro Albuminuria Reduction with valsartan) study assessed the reduction in urinary albumin excretion (UAE) with valsartan (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (valsartan: 58 &mu;g/min; amlodipine: 55.4 &mu;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &mu;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42 % (&ndash;24.2 &mu;g/min; 95 % CI: &ndash;40.4 to &ndash;19.1) with valsartan and approximately 3 % (&ndash;1.7 &mu;g/min; 95 % CI: &ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.<br />The valsartan Reduction of Proteinuria (DROP) study further examined the efficacy of valsartan in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2 diabetes, albuminuria (mean=102 &mu;g/min; 20-700 &mu;g/min) and preserved renal function (mean serum creatinine = 80 &mu;mol/l). Patients were randomized to one of 3 doses of valsartan (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of valsartan for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36 % from baseline with valsartan 160 mg (95 %CI: 22 to 47 %), and by 44 % with valsartan 320 mg (95 %CI: 31 to 54 %). It was concluded that 160-320 mg of valsartan produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.<br />Recent myocardial infarction<br />The VALsartan In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le; 40% by radionuclide ventriculography or &le; 35% by echocardiography or ventricular contrast angiography). Patients were randomized within 12 hours to 10 days after the onset of myocardial infarction symptoms to valsartan, captopril, or the<br />combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.<br />Valsartan was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the valsartan (19.9 %), captopril (19.5 %), and valsartan+captopril (19.3 %) groups. Combining valsartan with captopril did not add further benefit over captopril alone. There was no difference between valsartan and captopril in all-cause mortality based on age, gender, race, baseline therapies or underlying disease. Valsartan was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, and recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint.)<br />The safety profile of valsartan was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of valsartan-treated patients, 4.8% of valsartan+captopril-treated patients, and 3.4% of<br />captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of valsartan-treated patients, 1.3% in valsartan+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.<br />There was no difference in all-cause mortality or cardiovascular mortality or morbidity when beta- blockers were administered together with the combination of valsartan + captopril, valsartan alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.<br />12<br />Heart failure<br />Val-HeFT was a randomised, controlled, multinational clinical trial of valsartan compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter<br />(LVIDD) &gt;2.9 cm/m2. Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of valsartan in Val-HeFT was 254 mg. The study had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.<br />All cause mortality was similar (p=NS) in the valsartan (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in valsartan group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and valsartan.<br />In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with valsartan compared to placebo by 33% (95% CI: &ndash; 6% to 58%) (17.3% valsartan vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% valsartan vs. 42.5% placebo).<br />In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the valsartan (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with valsartan compared with placebo (31.0% vs. 36.3%).<br />In the overall Val-HeFT population, valsartan treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with valsartan had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in valsartan treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.<br />Paediatricpopulation<br />Hypertension<br />The antihypertensive effects of valsartan have been evaluated in four randomized, double-blind clinical studies in 561 paediatric patients from 6 to 18 years of age and 165 paediatric patients 1 to 6 years of age. Renal and urinary disorders, and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies.<br />Clinical experience in children at or above 6 years of age<br />In a clinical study involving 261 hypertensive paediatric patients 6 to 16 years of age, patients who weighed &lt;35 kg received 10, 40 or 80 mg of valsartan tablets daily (low, medium and high doses), and patients who weighed &ge;35 kg received 20, 80, and 160 mg of valsartan tablets daily (low, medium and high doses). At the end of 2 weeks, valsartan reduced both systolic and diastolic blood pressure in a dose-dependent manner.<br />Overall, the three dose levels of valsartan (low, medium and high) significantly reduced systolic blood pressure by 8, 10, 12 mm Hg from the baseline, respectively. Patients were re-randomized to either continue receiving the same dose of valsartan or were switched to placebo. In patients who continued to receive the medium and high doses of valsartan systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received the placebo treatment. In patients receiving the low dose of valsartan, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of valsartan was consistent across all the demographic<br />13<br />subgroups.<br />In another clinical study involving 300 hypertensive paediatric patients 6 to 18 years of age, eligible patients were randomized to receive valsartan or enalapril tablets for 12 weeks. Children weighing between &ge;18 kg and &lt;35 kg received valsartan 80 mg or enalapril 10 mg; those between &ge;35 kg and &lt;80 kg received valsartan 160 mg or enalapril 20 mg; those &ge;80 kg received valsartan 320 mg or enalapril 40 mg. Reductions in systolic blood pressure were comparable in patients receiving valsartan (15 mmHg) and enalapril (14 mm Hg) (non-inferiority p-value<br />&lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1 mmHg and 8.5 mmHg with valsartan and enalapril, respectively.<br />Clinical experience in children less than 6 years of age<br />Two clinical studies were conducted in patients aged 1 to 6 years with 90 and 75 patients, respectively. No children below the age of 1 year were enrolled in these studies. In the first study, the efficacy of valsartan was confirmed compared to placebo but a dose-response could not be demonstrated. In the second study, higher doses of valsartan were associated with greater BP reductions, but the dose response trend did not achieve statistical significance and the treatment difference compared to placebo was not significant.<br />Because of these inconsistencies, valsartan is not recommended in this age group (see section 4.8).<br />The EuropeanMedicines Agency has waived the obligation to submit the results of studies with valsartan in all subsets of the paediatric population in heart failure and heart failure after recent myocardial infarction.<br />See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Following oral administration of valsartan alone, peak plasma concentrations of valsartan are reached in 2&ndash;4 hours with tablets and 1-2 hours with solution formulation. Mean absolute bioavailability is 23 % and 39 % with tablets and solution formulation, respectively. Food decreases exposure (as measured by AUC) to valsartan by about 40 % and peak plasma concentration (Cmax) by about 50 %, although from about 8 h post dosing plasma valsartan concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and valsartan can therefore be given either with or without food.<br />Distribution:<br />The steady-state volume of distribution of valsartan after intravenous administration is about 17 litres, indicating that valsartan does not distribute into tissues extensively. Valsartan is highly bound to serum proteins (94&ndash;97 %), mainly serumalbumin.<br />Biotransformation:<br />Valsartan is not biotransformed to a high extent as only about 20 % of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10 % of the valsartan AUC). This metabolite is pharmacologically inactive.<br />Excretion:<br />Valsartan shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Valsartan is primarily eliminated by biliary excretion in faeces (about 83 % of dose) and renally in urine (about 13 % of dose), mainly as unchanged drug.<br />Following intravenous administration, plasma clearance of valsartan is about 2 l/h and its renal clearance is 0.62 l/h (about 30 % of total clearance). The half-life of valsartan is 6 hours.<br />In heart failure patients:<br />The average time to peak concentration and elimination half-life of valsartan in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of valsartan are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of valsartan following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.<br />Special populations<br />Elderly<br />A somewhat higher systemic exposure to valsartan was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance.<br />Impaired renal function<br />As expected for a compound where renal clearance accounts for only 30 % of total plasma clearance, no correlation was seen between renal function and systemic exposure to valsartan. Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore valsartan should be used with caution in these patients (see sections 4.2 and 4.4). Valsartan is highly bound to plasma protein and is unlikely to be removed by dialysis.<br />Hepaticimpairment<br />Approximately 70 % of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Valsartan does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma valsartan concentration versus degree of hepatic dysfunction. Valsartan has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).<br />Paediatricpopulation<br />In a study of 26 paediatric hypertensive patients (aged 1 to 16 years) given a single dose of a suspension of valsartan (mean: 0.9 to 2 mg/kg, with a maximum dose of 80 mg), the clearance (litres/h/kg) of valsartan was comparable across the age range of 1 to 16 years and similar to that of adults receiving the same formulation.<br />Impaired renal function<br />Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore valsartan is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance &gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.<br />In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).<br />In non-clinical safety studies, high doses of valsartan (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular<br />hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).<br />In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.<br />Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of valsartan which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of valsartan in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.<br />Paediatricpopulation<br />Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with valsartan at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life.<br />This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. The rats in the juvenile valsartan study were dosed up to day 70, and effects on renal maturation (postnatal 4-6 weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical<br />relevance in children &lt;1 year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core: microcrystalline cellulose (E-460), colloidal anhydrous silica, sorbitol (E-420),<br />magnesium carbonate (E-504), pregelatinised starch, povidone (E-1201), sodium stearyl<br />fumarate, sodium lauryl sulphate and crospovidone.<br />Coating: Opadry OY-L-28900 (lactose monohydrate, hypromellose (E-464), titanium dioxide<br />(E-171), macrogol).<br />valsartan cinfa 80 mg contains red iron oxide (E-172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at a temperature less than 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packaged in PVC-PE-PVDC (Triplex)/aluminium blisters.<br />Cinfaval 80 mg is supplied in packages containing 28 tablets (in 7 tablets blister packs).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The disposal of the unused drug and all materials in contact with it will be performed according<br />to the local regulations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LABORATORIOS CINFA, S.A.
Olaz-Chipi, 10 – Polígono Industrial Areta
31620 Huarte-Pamplona (Navarra)- Spain
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June-2013
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>